Blood test for autoantibodies shows promise in breast cancer

2019 09 12 23 41 0356 Cancer Cell Target 400

Screening for autoantibodies against tumor antigens in blood shows promise for detecting early-stage breast cancer, researchers at the University of Nottingham reported on November 3 at the U.K. National Cancer Research Institute (NCRI) Cancer Conference.

For the study, the researchers from the university's Centre of Excellence for Autoimmunity in Cancer screened for autoantibodies to 67 tumor-associated antigens in 180 samples, half of which were positive for breast cancer and half of which were controls, using optimized protein microarray technology. The results were delivered in a poster presentation on November 3 at the meeting, which is being held in Glasgow.

A panel of five tumor-associated antigens identified breast cancer in 29% of the cancer samples and determined that 84% of the control group samples were not cancerous. With a panel of nine, the researchers correctly identified 37% of the cancer samples and found that 79% of controls were cancer-free. They are now testing a panel of nine antigens in a study of 800 patients.

The autoantibody concept is applicable to other tumor types. Oncimmune's seven-antigen EarlyCDT-Lung blood test is being evaluated in a randomized controlled trial of 12,000 participants by the National Health Service (NHS) in Scotland.

Page 1 of 12
Next Page